[Drug prevention of recurrence in bladder tumors. Intravesical adriblastin instillation following transurethral resection of non-infiltrating bladder tumors].
29 patients were treated with intravesical adriamycin-instillations after transurethral resection of non-infiltrating bladder tumor. 50 mg Adriblastin were administered every four weeks during one year. In no case there were severe side-effects. Endoscopic controls were performed every three months. 12-28 months after beginning of therapy 6 recurrences (20,7%) were noted.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D014521:Urethra / Q000601:surgery; D001743:Urinary Bladder / Q000187:drug effects; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery*
D004317:Doxorubicin
Medikamentöse Rezidivprophylaxe bei Blasentumoren. Intravesikale Adriblastin-Instillation nach transurethraler Resektion nicht-infiltrierender Blasentumoren.